The first product off the line will be InnoCan’s patent-pending Relief & Go CBD Spray, which was developed by chief technology officer, Nir Avram.
"The patent-pending unique formulation of Relief & Go CBD Spray contains CBD isolate as anti inflammatory, magnesium as muscle relaxant, [and] menthol and camphor as analgesics to provide temporary relief of muscle and joint pain, before and after sports activity,” Avram said in a statement. “I believe this is an effective product, which will be very successful in the market."
The Israel-based company said it plans to start shipping product internationally within two weeks.
"The commencement of the production of our Derma CBD line is a significant milestone on the way to transforming our company from a research and development company to a commercial revenue generating enterprise,” CEO Iris Bincovich added.
“We expect to ship samples and products within 2 weeks to countries [such as the] UK, Germany, France [and the] US, among others. The anticipated revenues from our Derma Cosmetic Premium brands, Relieve & Go and Shir Beauty & Science, will result in revenue in the near future".
InnoCan Pharma, through its wholly-owned subsidiary, InnoCan Israel, is a pharmaceutical tech company developing products that harness the unique properties of cannabinoids combined with smart delivery formulations. InnoCan and Tel Aviv University are collaborating on developing a new exosome-based technology that targets both central nervous system disorders and the coronavirus (COVID-19).
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel